ArticleThe Journal of experimental medicine2012
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.
Article in The Journal of experimental medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Characterization of Human Cytomegalovirus (HCMV) Long Non-Coding RNA1.2 During Lytic Replication.Viruses · 2025Article
- Review
- Long non-coding RNA Snhg16 Lessens Ozone Curative Effect on Chronic Constriction Injury mice via microRNA-719/SCN1A axis.Molecular biotechnology · 2024Article
- Selective neurodegeneration generated by intravenous α-synuclein pre-formed fibril administration is not associated with endogenous α-synuclein levels in the rat brain.Brain pathology (Zurich, Switzerland) · 2023Article
- Human Cytomegalovirus RNA2.7 Is Required for Upregulating Multiple Cellular Genes To Promote Cell Motility and Viral Spread Late in Lytic Infection.Journal of virology · 2021Article
- Trojan Horse Delivery of 4,4'-Dimethoxychalcone for Parkinsonian Neuroprotection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Systemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease.Molecular psychiatry · 2021Article
- Human Cytomegalovirus Long Non-coding RNA1.2 Suppresses Extracellular Release of the Pro-inflammatory Cytokine IL-6 by Blocking NF-κB Activation.Frontiers in cellular and infection microbiology · 2020Article
- Serine residues at positions 162 and 166 of the rabies virus phosphoprotein are critical for the induction of oxidative stress in rabies virus infection.Journal of neurovirology · 2017Article
- Roles of LncRNAs in Viral Infections.Frontiers in cellular and infection microbiology · 2017Review
- The Cytomegalovirus protein pUL37×1 targets mitochondria to mediate neuroprotection.Scientific reports · 2016Article
- Long noncoding RNAs in viral infections.Virus research · 2016Review
- Noncoding RNA Regulation of Dopamine Signaling in Diseases of the Central Nervous System.Frontiers in molecular biosciences · 2016Review
- Rabies virus phosphoprotein interacts with mitochondrial Complex I and induces mitochondrial dysfunction and oxidative stress.Journal of neurovirology · 2015Article
- Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease.Parkinson's disease · 2015Article
- Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?The Journal of comparative neurology · 2014Review
- Developing epigenetic diagnostics and therapeutics for brain disorders.Trends in molecular medicine · 2013Review
- Neurodegenerative disease: Harnessing virus-mediated mitochondrial protection to combat neurodegeneration.Nature reviews. Drug discovery · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder that results in the loss of nigrostriatal dopamine neurons. The etiology of this cell loss is unknown, but it involves abnormalities in mitochondrial function. In this study, we have demonstrated that the administration of a novel noncoding p137 RNA, derived from the human cytomegaloviral β2.7 transcript, can prevent and rescue dopaminergic cell death in vitro and in animal models of PD by protecting mitochondrial Complex I activity. Furthermore, as this p137 RNA is fused to a rabies virus glycoprotein peptide that facilitates delivery of RNA across the blood-brain barrier, such protection can be achieved through a peripheral intravenous administration of this agent after the initiation of a dopaminergic lesion. This approach has major implications for the potential treatment of PD, especially given that this novel agent could have the same protective effect on all diseased neurons affected as part of this disease process, not just the dopaminergic nigrostriatal pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.